R&D expenses on financial statements show up in four places, and once you know the map you can pull the figures in a few minutes. The income statement carries the headline number as a line item within operating expenses. The notes to the financial statements break that number down by category. The balance sheet holds any R&D costs the company was allowed to capitalize as long-term assets. The cash flow statement shows what actually left the company in cash. For any publicly traded company, all four live inside the 10-K annual report and 10-Q quarterly report filed with the Securities and Exchange Commission, available for free on the SEC’s EDGAR system.1SEC.gov. About EDGAR
Public companies are required to file these reports under federal securities law.2Office of the Law Revision Counsel. 15 USC 78m – Periodical and Other Reports Pull up the most recent 10-K on EDGAR, and use the document’s search function for “research and development.” That single query will usually surface every relevant section in the filing.3SEC.gov. Search Filings
The Income Statement Line
Start with the Consolidated Statement of Operations. R&D typically appears as its own line inside operating expenses, sitting between gross profit and operating income. Under GAAP (ASC Topic 730), most R&D costs must be expensed in the period they are incurred rather than spread over future years, which is why the full amount hits the income statement in a single reporting period.4Internal Revenue Service. IRC 41 ASC 730 Research and Development Costs
The most useful thing to do with the number, once you have it, is to divide total R&D expense by total revenue. That ratio, sometimes called R&D intensity, tells you how many cents of every revenue dollar the company puts back into developing new products. Pharmaceutical and biotech companies routinely spend 15–25% of revenue on R&D. Software firms often run higher. An industrial manufacturer at 3–4% is normal for that sector. The figure only means something against a relevant peer group.
When the Line Is Not Labeled “R&D”
Not every company gives R&D its own line. Some fold it into Selling, General, and Administrative expenses. Others label it “Product Development,” “Software Development,” or “Engineering Research.”5Internal Revenue Service. FAQs – IRC 41 QREs and ASC 730 LBI Directive This tends to happen where R&D is small relative to overall operating costs, or where development activity blurs into ongoing operations. If you can’t find an obvious R&D line, skip to the footnotes. ASC 730 requires the total R&D amount to be disclosed somewhere in the filing, whether or not it gets its own line on the face of the income statement.4Internal Revenue Service. IRC 41 ASC 730 Research and Development Costs
The Notes to the Financial Statements
The Notes to Consolidated Financial Statements are where the single line becomes something you can actually analyze. Look for a note titled “Research and Development,” or check the “Summary of Significant Accounting Policies” note, which sets out how the company classifies these costs. If the income statement bundled R&D into something broader, the standalone figure is disclosed here.
The notes also frequently break down what the R&D dollars paid for. Common categories include personnel costs (salaries and benefits for scientists, engineers, and developers), materials and equipment (lab supplies, prototyping, depreciation on research equipment), contract services (third-party research organizations and consultants), and allocated indirect costs like facilities and utilities for research spaces. General administrative expenses unrelated to research are excluded.
That mix tells you something the top-line number cannot. A company weighted toward personnel and lab materials is running its own programs. A company where contract services dominate is outsourcing the technical work. The notes also disclose collaborative arrangements where R&D costs are shared with partners, which is common in pharmaceutical development and can make a company’s reported spending look smaller than the total research effort behind its pipeline.
Capitalized R&D on the Balance Sheet
Some R&D does not hit the income statement right away. It lands on the balance sheet as a long-term asset, usually inside “Intangible Assets” or listed near goodwill. Two situations account for most of what you’ll find there.
Software Development Costs
The treatment depends on who the software is for. Under ASC 985-20, software built for sale or licensing is expensed until it reaches “technological feasibility,” which in practice means a detailed program design or a working model. After that milestone, costs are capitalized until the product is available for general release. Companies using agile development often treat the working model as the feasibility gate, and because the gap between a working model and general release tends to be short, most of the spending still runs through the income statement.
Software built for the company’s own internal use follows ASC 350-40, which uses a three-stage framework. Preliminary-stage costs (planning, evaluating alternatives) are expensed. Once management authorizes and funds a project that is probable to be completed, application-development costs (coding, testing, installation) are capitalized. After the software goes live, training and routine maintenance return to being expensed.
In-Process R&D from Acquisitions
When one company acquires another, any in-process research and development at the target is recorded as an intangible asset at fair value on the acquisition date. This applies even if the acquired company had been expensing those same costs before the deal. The acquirer books them as assets. In-process R&D sits on the balance sheet as an indefinite-lived intangible until the project is either completed (at which point it starts being amortized) or abandoned (at which point it is written off). Costs incurred on the project after the acquisition date are expensed normally under ASC 730.
Patents, licenses, and other technology bought from third parties outside a business combination also appear as intangible assets and are amortized over their useful life, creating a recurring charge that flows through the income statement for years. Tracking capitalized development costs alongside acquired technology gives you a fuller picture of how much a company is investing in future products through its own work versus buying its way to innovation.
The Cash Flow Statement
The statement of cash flows shows the actual cash a company spent, which sometimes differs from the expense recognized on the income statement. R&D that was expensed flows through the operating activities section as part of net income adjusted for non-cash items. Capitalized development costs, such as internal-use software assets, show up in the investing activities section as capital expenditures. If a company capitalizes a meaningful chunk of its development work, reading only the income statement understates the true cash commitment.
Timing differences also surface here. A company may recognize R&D expense evenly across quarters while the underlying cash payments to contract research organizations or equipment vendors arrive in lumps. Pharmaceutical companies running expensive clinical trials often see cash outflows spike well before the corresponding expense hits the income statement. Reading the cash flow statement alongside the income statement gives you a more grounded view of what R&D is costing in real dollars.
The MD&A for the Why Behind the Numbers
The Management’s Discussion and Analysis section is where executives explain the R&D figures. Regulation S-K, Item 303 requires companies to describe known trends, events, or uncertainties likely to affect financial results, and shifts in R&D spending routinely fall into that bucket.6eCFR. 17 CFR 229.303 – Item 303 Management Discussion and Analysis of Financial Condition and Results of Operations You’ll find explanations of why spending rose or fell, which programs are in early research versus late-stage development, and how management expects R&D investments to translate into future revenue.
The MD&A typically covers three fiscal years of comparative data, though emerging growth companies in their initial filings may discuss only two.6eCFR. 17 CFR 229.303 – Item 303 Management Discussion and Analysis of Financial Condition and Results of Operations That multi-year view is useful for spotting directional shifts, such as a pharmaceutical company ramping spending on a late-stage clinical trial or a tech firm winding down one platform to fund another. Executives also use this section to discuss external factors shaping R&D decisions: patent law changes, new regulatory requirements, competitive pressures, and shifts in customer demand. For companies in regulated industries like medical devices or defense, the MD&A often maps specific regulatory milestones to the R&D budget.
Why the Book Figure Differs from the Tax Figure
Anyone comparing a company’s financial-statement R&D to what it reports on its tax return will see the two numbers diverge. Financial statements follow GAAP under ASC 730, which requires immediate expensing of most R&D. Tax returns follow Internal Revenue Code Section 174, and those rules changed substantially in recent years.
For 2026, domestic research and experimental expenditures can once again be deducted immediately for tax purposes, after a period from 2022 through 2024 when companies were required to capitalize and amortize them over five years. Pub. L. 119-21 enacted new Section 174A restoring immediate deductibility for domestic R&D, effective for tax years beginning after December 31, 2024. Companies can alternatively elect to capitalize and amortize domestic R&D over at least 60 months. Foreign research expenditures must still be capitalized and amortized over 15 years.7Office of the Law Revision Counsel. 26 USC 174 – Amortization of Research and Experimental Expenditures
The pool of expenses that counts as R&D for tax purposes is also broader than the GAAP version. Section 174 captures indirect costs like overhead, utilities, and attorney fees tied to the research, plus all software development expenses. On top of the deduction, companies performing qualified research can claim a tax credit under Section 41, calculated as a percentage of qualified research expenses above a base amount.8Internal Revenue Service. Instructions for Form 6765 – Credit for Increasing Research Activities The tax footnote or income tax reconciliation note in the financial statements is where R&D tax credits and any deferred tax assets from book-tax timing differences are disclosed, so that’s the last place to check when your goal is a complete picture of how R&D is running through both sets of books.